Graefe's Archive for Clinical and Experimental Ophthalmology

, 245:1727

Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity

Authors

  • Eun Jee Chung
    • The Institute of Vision ResearchDepartment of Ophthalmology,Yonsei University College of Medicine
  • Ji Hyun Kim
    • The Institute of Vision ResearchDepartment of Ophthalmology,Yonsei University College of Medicine
  • Hyun Seok Ahn
    • The Institute of Vision ResearchDepartment of Ophthalmology,Yonsei University College of Medicine
    • The Institute of Vision ResearchDepartment of Ophthalmology,Yonsei University College of Medicine
    • Department of OphthalmologyYonsei University College of Medicine
Case Report

DOI: 10.1007/s00417-007-0661-y

Cite this article as:
Chung, E.J., Kim, J.H., Ahn, H.S. et al. Graefes Arch Clin Exp Ophthalmol (2007) 245: 1727. doi:10.1007/s00417-007-0661-y

Abstract

Background

This report describes the use of combined laser photocoagulation and intravitreal bevacizumab administration for aggressive zone I retinopathy of prematurity (ROP).

Methods

A male patient, born at 25 weeks gestation with a birth weight of 884 g, received indirect laser photocoagulation and a 0.75 mg intravitreal bevacizumab injection to each eye for aggressive stage 3 zone I ROP. Structural outcomes were evaluated 3 months after treatment.

Results

At 3-month follow-up, treatment had resulted in ROP regression, prompt resolution of plus signs and neovascular proliferation in both eyes, and no signs of systemic or ocular adverse events.

Conclusions

The combination of indirect laser photocoagulation and intravitreal bevacizumab injection was well tolerated and induced prompt regression of aggressive zone I ROP.

Keywords

Retinopathy of prematurityIndirect laser photocoagulationIntravitreal bevacizumab injection

Copyright information

© Springer-Verlag 2007